Latest Regulatory News

The Star Entertainment Group reported a 10% drop in H1 FY26 revenue, offset by a 71% improvement in EBITDA, while navigating ongoing licence suspensions and a critical refinancing process.

TPC Consolidated and Wollar Solar have mutually terminated their acquisition agreement after unmet conditions, but both remain open to future partnerships.

Complii FinTech Solutions reported a $1.35 million loss for H1 FY26 alongside a 6% increase in annual recurring revenue, driven by strategic platform upgrades and expanding client engagement.

Platformo Ltd reported a modest 5% revenue increase in 2025 driven by its Malaysian subsidiary Biztrak, but faced a higher net loss due to regulatory delays and increased corporate advisory costs.

Freedom Care Group Holdings outlines a strategic recovery plan following the suspension of its securities and liquidation of its main operating subsidiary, aiming to restore shareholder value and regain ASX listing.

Betashares Capital Ltd has announced the final distribution amounts for February 2026 across a broad range of its ETFs listed on the ASX AQUA market, alongside details on the Distribution Reinvestment Plan.

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.

Vmoto Limited reported an 18% revenue decline to $46.8 million and a $9.9 million net loss in FY25, while accelerating its transformation into a full-stack electric mobility solutions provider with new global partnerships and product innovations.

Orion Equities reported a modest loss of $11,051 for the half-year ending December 2025, with net tangible asset backing per share holding steady at $0.42. The company’s investment portfolio, notably in Strike Resources and Bentley Capital, remains central to its financial position.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.